Public Profile

CellBion Co., Ltd.

CellBion Co., Ltd., headquartered in South Korea (KR), is a prominent player in the biotechnology industry, specialising in innovative cell therapy solutions. Founded in 2015, the company has rapidly established itself as a leader in regenerative medicine, focusing on the development and commercialisation of advanced cellular products. With a strong operational presence in Asia and beyond, CellBion offers unique services in cell culture and manipulation, catering to both research and clinical applications. Their flagship products, which include cutting-edge stem cell lines and customised cell solutions, are distinguished by their high purity and efficacy, setting new standards in the field. Recognised for its commitment to quality and innovation, CellBion has achieved significant milestones, positioning itself as a trusted partner in the global biotechnology landscape.

DitchCarbon Score

How does CellBion Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

20

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

CellBion Co., Ltd.'s score of 20 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

CellBion Co., Ltd.'s reported carbon emissions

CellBion Co., Ltd., headquartered in South Korea (KR), currently does not have available carbon emissions data for recent years, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions figures to analyse. In the absence of concrete emissions data, it is essential to highlight that CellBion Co., Ltd. is committed to addressing climate change through various initiatives. However, specific reduction targets or commitments, such as those aligned with the Science Based Targets initiative (SBTi), have not been disclosed. As the company continues to navigate its environmental responsibilities, it is crucial for stakeholders to monitor future announcements regarding their carbon emissions and climate commitments.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. CellBion Co., Ltd.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for CellBion Co., Ltd. is in KR, which we do not have grid emissions data for.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

CellBion Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

RadioMedix, Inc.

US
Health and social work services (85)
Updated 3 days ago

ABX advanced biochemical compounds GmbH

DE
Research and development services (73)
Updated 3 months ago
DitchCarbon Score

Clarity Pharmaceuticals Ltd

AU
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Telix Pharmaceuticals

US
Chemicals nec
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers